TTrialPathMatch Me to Trials
← Back to trials
RecruitingSevere Sickle Cell DiseaseBone Marrow Failure SyndromesMetabolic Disorders

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Eligible age

0–21 yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.

Sponsor: Washington University School of Medicine

You may qualify if…

  • ✓ Nonmalignant disorder requiring bone marrow transplant including bone marrow failure syndromes, metabolic disorders, immunologic disorders, or hemoglobinopathy
  • ✓ For patients with sickle cell disease, must have one of the following severe manifestations:
  • ✓ 1. Overt or silent stroke or persistently elevated transcranial doppler velocities despite transfusion therapy
  • ✓ 2. Recurrent acute chest syndrome with significant respiratory compromise each time
  • ✓ 3. Sickle nephropathy
  • ✓ 4. Recurrent admissions for vaso-occlusive episodes resulting in prolonged opioid use and poor quality of life with interrupted school attendance activity
  • ✓ 5. Red cell alloimmunization with the need for chronic transfusions
  • ✓ 6. Recurrent osteonecrosis or multiple joint involvement from avascular necrosis

You may not qualify if…

  • ✕ Patients who have an HLA-identical sibling who is able and willing to donate bone marrow
  • ✕ Patients with cirrhosis or established bridging fibrosis of the liver or active hepatitis
  • ✕ Uncontrolled bacterial, viral, or fungal infection within 6 weeks prior to enrollment
  • ✕ Evidence of HIV infection or known HIV positive serology
  • ✕ Patients who have received a previous stem cell transplant
  • ✕ Patients who have received an investigational drug or device or off-label use of a drug or device within 3 months of enrollment
  • ✕ Females who are pregnant or breast feeding
  • ✕ Patients with active autoimmune disease (e.g. sarcoidosis, lupus, scleroderma)

Where it's recruiting

Connecticut

New Haven

Delaware

Wilmington

Michigan

Grand Rapids

Missouri

St Louis

Source: ClinicalTrials.gov · NCT03128996 · last updated 2026-05-29